KAUST signed an MoU with MISA and Novo Nordisk at the Riyadh Global Medical Biotechnology Summit 2023. The agreement aims to address healthcare challenges in Saudi Arabia and develop the biotech and pharma sector through knowledge transfer and research. A key objective is to establish a Novo Nordisk Center of Excellence focused on obesity and metabolic research. Why it matters: The partnership will boost Saudi Arabia's Vision 2030 goals of creating tech-driven industries and improving health outcomes through biotechnology.
KAUST postdoctoral fellow Elisabetta Fiacco won the Best Poster Prize at the Spetses Summer School 2018 on Chromatin and Metabolism for her research on the role of carbohydrate-responsive element binding protein (ChRBP) during the onset of type 2 diabetes. Fiacco's research at KAUST, under Assistant Professor Antonio Adamo, uses human induced pluripotent stem cells to understand the epigenetic and transcriptional mechanisms dysregulated in type 2 diabetes. She also gave a 15-minute oral presentation on her work at the event, which gathered over 80 participants from top global universities. Why it matters: This recognition highlights KAUST's contribution to cutting-edge research in regenerative medicine and the study of metabolic disorders prevalent in the region.
KAUST's Laboratory of Stem Cells and Diseases, led by Assistant Professor Antonio Adamo, uses induced pluripotent stem cells (iPSCs) to model diseases like diabetes. The lab employs a reprogramming technique to revert patient fibroblasts into iPSCs, enabling the study of disease progression in vitro. Adamo's research focuses on enzymes and disregulated transcriptional/epigenetic mechanisms to understand disease onset. Why it matters: This research contributes to regenerative medicine and offers insights into metabolic diseases relevant to the GCC region.
KAUST and the Saudi Food and Drug Authority (SFDA) have partnered to develop a new method using nuclear magnetic resonance (NMR) to detect adulterants in olive oil. The method aims to identify and quantify vegetable oils mixed with olive oil, addressing concerns about the mislabeling of olive oil in the Saudi market. KAUST's comprehensive suite of NMR machines was critical for the project. Why it matters: This collaboration enhances food safety and quality control in Saudi Arabia, a major olive oil importer, and helps to ensure consumers receive authentic, high-quality products.
Dr. John Bedbrook of DiCE Molecules LLC spoke at KAUST about the challenges of feeding a growing population with increasingly stressed arable land. He noted the increasing demand for meat in emerging economies exacerbates the problem. Bedbrook emphasized the role of genetics and hybridization in improving crop yields and quality to address food security. Why it matters: Investments in agricultural biotechnology are crucial for the GCC region to enhance food security and reduce reliance on imports amid changing climate conditions.
KAUST Professor Pierre Magistretti participated in the U.S.-Saudi Arabia Business Leaders Virtual Forum, organized by the U.S. Chamber of Commerce and the Saudi Ministry of Investment. Magistretti spoke on a panel about healthcare innovation alongside representatives from Pfizer, Abbott, and the Saudi Ministry of Investment. KAUST's Smart-Health Initiative (SHI) aims to translate scientific discoveries into clinical tools. Why it matters: This participation highlights KAUST's growing role in shaping healthcare innovation within the Kingdom and fostering international collaborations in the field.
KAUST researchers led by Dr. Niveen Khashab have developed thermosensitive liposomes for controlled drug release, particularly in cancer therapies. The liposomes are designed to release drugs only when they reach heated tumor tissue, minimizing systemic side effects. Cholesterol moieties are used as anchors to create a "nail" or "comb" effect, enabling temperature-triggered drug release inside cells. Why it matters: This targeted drug delivery system could significantly improve the efficacy and reduce the toxicity of cancer treatments.
The Russian Immune Diversity Atlas project aims to profile immune cells from people of different ancestries at a multiomics level. The goal is to reconstruct a reference atlas of the healthy immune system and investigate its perturbations in Type II Diabetes (T2D). The project seeks to identify novel mechanisms and genetic/epigenetic markers for early T2D diagnostics, prognosis, and therapy as part of the international Human Cell Atlas. Why it matters: Addressing genetic diversity in biomedical research, particularly in the context of the Human Cell Atlas, is crucial for personalized medicine and ensuring that treatments are effective across diverse populations in the Middle East and globally.